Adalimumab: profile and news

FDA clears Rituxan for rheumatoid arthritis Mar 1, 2006
...based on tumour necrosis factor blockers, namely Centocor's Remicade (infliximab), Amgen/Wyeth's Enbrel (etanercept) and Abbott Laboratories' Humira (adalimumab ... - Pharma Times (subscription),

Genentech, Biogen Idec Gain Approval Of Rituxan In RA Mar 1, 2006
...to prior treatment with methotrexate and one or more TNF antagonist therapies such as Enbrel (etanercept, from Amgen Inc.), Humira (adalimumab, from Abbott ... - BioWorld Online (subscription),

New US Patent 6,982,089 Issued - Describing a Novel Biotechnology ... Feb 20, 2006
This patent also includes claims involving the perispinal use of certain biologic TNF inhibitors, including adalimumab and certolizumab pegol, for treating ... - PR Web (press release),

Rheumatic Diseases Remain a Significant Cause of Chronic Illness ... Feb 22, 2006
Juvenile arthritis is the next indication due for approval for blockbuster biologic therapies Remicade (infliximab) and Humira (adalimumab). ... - Business Wire (press release),

Cambridge Antibody Technology Group plc Announces First Quarter ... Feb 5, 2006
HUMIRA(R) (adalimumab) is a fully human anti-TNF(alpha) monoclonal antibody, isolated and optimised by CAT in collaboration with Abbott and now approved for ... - MSN Money

Better Fix For Rheumatoid Arthritis Feb 16, 2006
...which contribute to inflammation. Examples are etanercept, infliximab, adalimumab and anakinra. • Protein-A Immunoadsorption Therapy ... - WFtv.com,

Cambridge Antibody Technology Group plc Announces First Quarter ... Feb 5, 2006
HGSI has reported progress with LymphoStat-B and HGS-ETR1." HUMIRA(R) (adalimumab) is a fully human anti-TNF(alpha) monoclonal antibody, isolated and optimised ... - PR Newswire (press release),

Inflammatory Diseases - Both Chronic Diseases, Such as Rheumatoid ... Feb 1, 2006
CD). Nearly all sales were generated by the three available anti-TNF-a agents: etanercept, infliximab, and adalimumab. -- Twenty ... - Genetic Engineering News,

Other information

Indication
For treatment of rheumatoid arthritis

Pharmacology
Used in the treatment of rheumatoid arthritis. Elevated levels of TNF are found in the synovial fluid of rheumatoid arthritis patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of the disease. Adalimumab binds specifically to TNF-alpha and blocks its general cytokine effects, thereby reducing TNF-induced inflammation and halting the joint destruction.

Mechanism Of Action
Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement.

Drug Category
Immunomodulatory Agents; Antirheumatic Agents; unclassified therapeutic agents (92:00.00)

Brand Names/Synonyms
Ig gamma-1 chain C region; Humira (Abbott Laboratories)

Dosage Forms
Solution

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
Humanized anti-TNF antibody (D2E7)

Chemical Formula
C6428H9912N1694O1987S46 >Mouse-Human chimeric chain 1 Anti-TNF alpha VL >Mouse-Human chimeric chain 2 Anti-TNF alpha VH >Mouse-Human chimeric chain 2 Anti-TNF alpha VL

Half Life
10-20 days.

Drug Type
Approved Drug

# Accession No
BIOD00049

CAS Registry Number
331731-18-1